Isotechnika Pharma Inc IPHAF

And here is your confirmation

[That Other Guy]

Funny... Yahoo had this before Stockhouse. Thursday January 27, 12:09 pm Eastern Time Company Press Release Isotechnika Inc. Announces The IND Filing Of Its New Immunosupressive Drug ISAtx247 To The Canadian Health Protection Branch EDMONTON, ALBERTA--Dr. Randall Yatscoff, President of Isotechnika Inc. is pleased to announce the IND filing of Isotechnika's new immunosuppressive drug ISAtx247 to the Health Protection Branch of Canada to obtain approval to commence human clinical trials with the drug. A parallel filing with the U.S. Food and Drug administration will follow within the next few months. `` This represents a significant milestone achievement for Isotechnika as it is the first drug in our pipeline to complete pre-clinical testing prior to entering human clinical trials. It moves the corporation out of the realm of a pre-clinical drug discovery and research company to one that is involved in human based trials. The ability of Isotechnika to complete the pre-clinical trials so early in the genesis of our company speaks to the hard work, dedication and diligence of our core group of highly trained scientists'' said Dr. Yatscoff. ISAtx247 is a novel immunosuppressive drug, which is designed to be used for prevention of organ rejection after transplantation and for treatment of autoimmune diseases such as arthritis and psoriasis to name a few. Based on the completed pre-clinical studies, ISAtx247 demonstrates superior efficacy and reduced toxicity when compared with presently used medications such as Cyclosporine for prevention of organ rejection after transplantation and for treatment of autoimmune diseases. Current annual worldwide sales of Cyclosporine are in excess of $2 billion USD. ``It is anticipated that the drug will commence Phase 1 trials in the spring of 2000. Subsequent to the completion of Phase 1 trials it is our intention to develop the drug for a number of transplant and autoimmune indications. The significant in-house expertise in immunosuppressive drug research under the direction of Dr. Yatscoff who has greater than 20 years experience in this area should ensure rapid progression of the drug through the human clinical trial phases'' said Dr. Robert Foster, Chairman and CEO of the Corporation. Isotechnika is a life sciences company headquartered in Edmonton, Alberta developing novel drugs and diagnostic products. The development costs of Isotechnika's lead drug is being supported in part, by sales of the company's breath-based point-of-care diagnostic kits. These kits aid in the diagnosis of ulcers, diabetes and insulin resistance, fat malabsorption, small bowel bacterial overgrowth, and lactose intolerance. Isotechnika's diagnostic kits are designed to be used with a point-of-care instrument developed by the company. The revenue stream resulting from licensing and strategic alliances for sales of a diagnostics also assist the therapeutic product R&D efforts. -------------------------------------------------------------------------------- Contact: Isotechnika Inc. Dr. Robert Foster Chairman & CEO [phone] [phone] [e-mail] or Isotechnika Inc. Dr. Randall Yatscoff President [phone] (780) 484- 4105 [e-mail]